Patients Exploring mixed episodes in bipolar I disorder: When mania a... One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.
Patients World Bipolar Day: Recognising bipolar I disorder and addres... BD-I is a brain-based condition that affects mood and energy regulation to an extent that disrupts daily life.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
